AHA op-ed in Medical Economics sets the record straight on 340B program growth and the role of drug companies

“As pharmaceutical companies throw stone after stone at the 340B program, they should beware of their own glass house. Their complaints ring hollow when it is clear that their own actions are driving growth in the program,” says an op-ed in Medical Economics authored by Bharath Krishnamurthy, AHA director of health policy and analytics, and Megha Parikh, AHA associate director of health analytics and policy.

“…Policymakers and the public should reject the fabrications perpetuated by pharmaceutical companies,” Krishnamurthy and Parikh write. “Instead, they should work to protect and support the 340B program and the benefits it affords to countless patients and communities across the country.”